Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.

Elhassan A, Mohamed AB, Mahgoub A, Singh A, Ali I

Open source

DOI
10.7759/cureus.117614
Published
2026 Oct
Container
Cureus
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7759/cureus.117614,
  title = {Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.},
  author = {Elhassan A and Mohamed AB and Mahgoub A and Singh A and Ali I},
  year = {2026},
  journal = {Cureus},
  doi = {10.7759/cureus.117614},
  url = {https://doi.org/10.7759/cureus.117614}
}

RIS

TY  - JOUR
TI  - Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.
AU  - Elhassan A
AU  - Mohamed AB
AU  - Mahgoub A
AU  - Singh A
AU  - Ali I
PY  - 2026
JO  - Cureus
DO  - 10.7759/cureus.117614
UR  - https://doi.org/10.7759/cureus.117614
ER  - 

APA

A, E., AB, M., A, M., A, S., & I, A. (2026). Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.. Cureus. https://doi.org/10.7759/cureus.117614

Source records